1 January 2022 in BioMed Research International
Met proto‐oncogene (MET) amplification and tyrosine‐protein kinase Met (c‐Met) overexpression confer gefitinib resistance in non‐small cell lung cancer (NSCLC). The natural product Licochalcone A (Lico A) exhibits a broad range of inhibitory effects against various tumors. However, the effects of Lico A on c‐Met signaling and gefitinib resistance in NSCLC remain unclear. In the present study, Lico A efficiently overcame gefitinib‐acquired resistance in NSCLC cells by suppressing c‐Met signaling. Lico A decreased cell viability and colony formation dose‐dependently and impaired in vivo tumorigenesis of gefitinib‐resistant HCC827 and PC‐9 cells. Furthermore, Lico A induced intrinsic apoptosis and upregulated the protein expression levels of cleaved poly (ADP‐ribose) polymerase and cleaved caspase 3. Lico A promoted the interaction between c‐Met and E3 ligase c‐Casitas B‐lineage lymphoma (Cbl), which enhanced c‐Cbl‐mediated c‐Met ubiquitination and degradation. Depletion of c‐Cbl compromised Lico A‐induced c‐Met ubiquitination and its inhibitory efficacy in gefitinib‐resistant NSCLC cells. Taken together, the results suggest that Lico A is a promising antitumor agent that might be used to overcome c‐Met overexpression‐mediated gefitinib resistance in NSCLC cells.
1 January 2023 in The American Journal of Chinese Medicine